Skip to content
CIK - Cytokine-induced killer
Universität Bonn
Universitätsklinikum Bonn

References

Chen, C.-L., Pan, Q.-Z., Weng, D.-S., Xie, C.-M., Zhao, J.-J., Chen, M.-S., . . . Tang, Y. (2018). Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. Oncoimmunology, 7(4), e1417721.


Chen, D., Sha, H., Hu, T., Dong, S., Zhang, J., Liu, S., . . . Jing, C. (2018). Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer. Cell death & disease, 9(3), 1-12.


Chen, F., Yang, M., Song, Q., Wu, J., Wang, X., Zhou, X., . . . Zhao, Y. (2017). Enhanced antitumor effects and improved immune status of dendritic cell and cytokine‑induced killer cell infusion in advanced cancer patients. Molecular and clinical oncology, 7(5), 903-910.


Chen, Y., Lin, W.-s., Zhu, W.-f., Lin, J., Zhou, Z.-f., Huang, C.-z., . . . Ye, Y.-b. (2016). Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer. Immunologic research, 64(1), 251-259.


Chung, M. J., Park, J. Y., Bang, S., Park, S. W., & Song, S. Y. (2014). Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunology, Immunotherapy, 63(9), 939-946.


Cui, J., Li, L., Wang, C., Jin, H., Yao, C., Wang, Y., . . . Wang, G. (2015). Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma. Cytotherapy, 17(7), 979-988.


Dong, M., Liang, D., Li, Y., Kong, D., Kang, P., Li, K., . . . Zhang, Y. (2012). Autologous dendritic cells combined with cytokine-induced killer cells synergize low-dose chemotherapy in elderly patients with acute myeloid leukaemia. Journal of International Medical Research, 40(4), 1265-1274.


Gao, D., Li, C., Xie, X., Zhao, P., Wei, X., Sun, W., . . . Zhao, R. (2014). Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PloS one, 9(4).


Gu, Y., Lv, H., Zhao, J., Li, Q., Mu, G., Li, J., . . . Zhang, Y. (2017). Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC). International immunopharmacology, 50, 263-269.


Guo, Z., Liu, H., He, X.-P., Tan, X.-H., Zhou, Y., Chen, X., . . . Chen, H.-R. (2011). A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma. Oncology letters, 2(3), 531-536.


Hao, M., Lin, H., Chen, Q., Ye, Y., Chen, Q., & Chen, M. (2010). Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chin J Cancer, 29(2), 172-177.


Hong, W., Na-na, H., & Xin-hua, C. (2016). Evaluation on the Clinical Efficacy of Dendritic Cell-Activated Cytokine-Induced Killer Cells Combined with Conventional Therapy in the Treatment of Malignant Tumors. Journal of International Translational Medicine, 4(2), 127-131.


Huang, J., Kan, Q., Zhao, X., Zhang, Z., Yang, S., Li, H., . . . Zhang, Y. (2017). Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer. International immunopharmacology, 46, 170-177.


Hui, D., Qiang, L., Jian, W., Ti, Z., & Da-Lu, K. (2009). A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Digestive and liver disease, 41(1), 36-41.


Introna, M., Borleri, G., Conti, E., Franceschetti, M., Barbui, A. M., Broady, R., . . . Biagi, E. (2007). Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica, 92(7), 952-959.


Introna, M., Lussana, F., Algarotti, A., Gotti, E., Valgardsdottir, R., Micò, C., . . . Delaini, F. (2017). Phase II study of sequential infusion of donor lymphocyte infusion and cytokine-induced killer cells for patients relapsed after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 23(12), 2070-2078.


Introna, M., Pievani, A., Borleri, G., Capelli, C., Algarotti, A., Micò, C., . . . Rambaldi, A. (2010). Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biology of Blood and Marrow Transplantation, 16(11), 1603-1607.


Jiang, J., Xu, N., Wu, C., Deng, H., Lu, M., Li, M., . . . Xu, J. (2006). Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer research, 26(3B), 2237-2242.


Jiang, J.-T., Shen, Y.-P., Wu, C.-P., Zhu, Y.-B., Wei, W.-X., Chen, L.-J., . . . Zhang, X.-G. (2010). Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World journal of gastroenterology: WJG, 16(48), 6155.


Jiang, N., Qiao, G., Wang, X., Morse, M. A., Gwin, W. R., Zhou, L., . . . Zhou, X. (2017). Dendritic cell/cytokine-induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: a prospective study. Clinical Cancer Research, 23(17), 5066-5073.


Jin, C., Li, J., Wang, Y., Chen, X., Che, Y., Liu, X., . . . Sriplung, H. (2014). Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy. Asian Pac J Cancer Prev, 15(15), 6009-6014.


Kong, D.-S., Nam, D.-H., Kang, S.-H., Lee, J. W., Chang, J.-H., Kim, J.-H., . . . Kim, J.-M. (2017). Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget, 8(4), 7003.


Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., . . . Arai, S. (2011). Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 17(11), 1679-1687.


Lee, J. H., Lee, J.-H., Lim, Y.-S., Yeon, J. E., Song, T.-J., Yu, S. J., . . . Lee, J. W. (2015). Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology, 148(7), 1383-1391. e1386.


Leemhuis, T., Wells, S., Scheffold, C., Edinger, M., & Negrin, R. S. (2005). A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 11(3), 181-187.


Li, C., Zhu, D., Zhao, Y., Guo, Q., Sun, W., Li, L., . . . Zhao, P. (2019). Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response. Immunological Investigations, 1-13.


Li, H., Huang, L., Liu, L., Wang, X., Zhang, Z., Yue, D., . . . Huang, J. (2017). Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma. Cancer Immunology, Immunotherapy, 66(3), 299-308.


Li, H., Wang, C., Yu, J., Cao, S., Wei, F., Zhang, W., . . . Ren, X.-b. (2009). Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy, 11(8), 1076-1083.


Li, N., Tian, Y.-W., Xu, Y., Meng, D.-D., Gao, L., Shen, W.-j., . . . Xu, Z.-Q. (2019). Combined Treatment with Autologous CIK Cells, Radiotherapy and Chemotherapy in Advanced Cervical Cancer. Pathology & Oncology Research, 25(2), 691-696.


Li, R., Wang, C., Liu, L., Du, C., Cao, S., Yu, J., . . . Li, H. (2012). Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunology, Immunotherapy, 61(11), 2125-2133.


Li, Y., Pan, K., Liu, L.-z., Li, Y.-q., Gu, M.-f., Zhang, H., . . . Li, J.-j. (2015). Sequential cytokine-induced killer cell immunotherapy enhances the efficacy of the gemcitabine plus cisplatin chemotherapy regimen for metastatic nasopharyngeal carcinoma. PloS one, 10(6).


Lin, T., Song, C., Chuo, D.-y., Zhang, H., & Zhao, J. (2016). Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. Tumor Biology, 37(4), 4367-4372.


Linn, Y., Niam, M., Chu, S., Choong, A., Yong, H., Heng, K., . . . Suck, G. (2012). The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone marrow transplantation, 47(7), 957-966.


Linn, Y.-C., Yong, H.-X., Niam, M., Lim, T.-J., Chu, S., Choong, A., . . . Loh, Y. (2012). A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy, 14(7), 851-859.


Liu, H., Song, J., Yang, Z., & Zhang, X. (2013). Effects of cytokine‑induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Experimental and therapeutic medicine, 6(4), 953-956.


Liu, J., Li, H., Cao, S., Zhang, X., Yu, J., Qi, J., . . . Hao, X. (2014). Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. Journal of immunotherapy, 37(2), 115-122.


Liu, L., Zhang, W., Qi, X., Li, H., Yu, J., Wei, S., . . . Ren, X. (2012). Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clinical Cancer Research, 18(6), 1751-1759.


Liu, Y., Liu, H., Liu, H., He, P., Li, J., Liu, X., . . . Wang, H. (2016). Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients> 65 years old. Oncology letters, 12(6), 5205-5210.


Lu, X.-c., Yang, B., Yu, R.-l., Chi, X.-h., Tuo, S., Tuo, C.-w., . . . Fu, X.-b. (2012). Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma. Cell biochemistry and biophysics, 62(1), 257-265.


Luo, H., Gong, L., Zhu, B., Huang, Y., Tang, C., Yu, S., . . . Zhou, X. (2016). Therapeutic outcomes of autologous CIK cells as a maintenance therapy in the treatment of lung cancer patients: A retrospective study. Biomedicine & Pharmacotherapy, 84, 987-993.


Luo, Y., Zeng, H.-Q., Shen, Y., Zhang, P., Lou, S.-F., Chen, L., & Deng, J.-C. (2016). Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: a phase I study in patients with relapsed/refractory hematologic malignancies. Leukemia research, 48, 6-10.


Mai, H.-X., Mei, G.-H., Zhao, F.-L., Li, B.-T., Tang, Y.-Y., Zhang, B., . . . Chen, L.-J. (2018). Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy. Journal of cancer research and therapeutics, 14(9), 427.


Mu, Y., Wang, W.-h., Xie, J.-p., Zhang, Y.-x., Yang, Y.-p., & Zhou, C.-h. (2016). Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: a randomized Phase II study. OncoTargets and therapy, 9, 4617.


Narayan, R., Benjamin, J. E., Shah, O., Tian, L., Tate, K., Armstrong, R., . . . Negrin, R. S. (2019). Donor-derived cytokine-induced killer cell infusion as consolidation after nonmyeloablative allogeneic transplantation for myeloid neoplasms. Biology of Blood and Marrow Transplantation, 25(7), 1293-1303.


Niu, Q., Wang, W., Li, Y., Qin, S., Wang, Y., Wan, G., . . . Zhu, W. (2011). Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. International immunopharmacology, 11(4), 449-456.


Olioso, P., Giancola, R., Di Riti, M., Contento, A., Accorsi, P., & Iacone, A. (2009). Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematological oncology, 27(3), 130-139.


Pan, C., Huang, Z., Li, W., Zhao, M., Zhou, Q., Xia, J., & Wu, P. (2010). Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chin J Cancer, 29(6), 596-602.


Pan, K., Guan, X.-X., Li, Y.-Q., Zhao, J.-J., Li, J.-J., Qiu, H.-J., . . . Huang, L.-X. (2014). Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clinical Cancer Research, 20(11), 3003-3011.


Pan, K., Li, Y.-Q., Wang, W., Xu, L., Zhang, Y.-J., Zheng, H.-X., . . . Li, J.-J. (2013). The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Annals of surgical oncology, 20(13), 4305-4311.


Pfeffermann, L.-M., Pfirrmann, V., Huenecke, S., Bremm, M., Bonig, H., Kvasnicka, H.-M., . . . Rettinger, E. (2018). Epstein-Barr virus–specific cytokine-induced killer cells for treatment of Epstein-Barr virus–related malignant lymphoma. Cytotherapy, 20(6), 839-850.


Qiao, G., Wang, X., Zhou, L., Zhou, X., Song, Y., Wang, S., . . . Song, J. (2019). Autologous dendritic cell-cytokine induced killer cell immunotherapy combined with S-1 plus cisplatin in patients with advanced gastric cancer: A prospective study. Clinical Cancer Research, 25(5), 1494-1504.


Qiu, Y., Xu, M.-B., Yun, M. M., Wang, Y.-Z., Zhang, R.-M., Meng, X.-K., . . . Yun, S. (2011). Hepatocellular carcinoma-specific immunotherapy with synthesized α1, 3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World journal of gastroenterology: WJG, 17(48), 5260.


Qiu, Y., Yun, M. M., Dong, X., Xu, M., Zhao, R., Han, X., . . . Liu, C. (2016). Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1, 3-galactosyl epitope–enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy. Cytotherapy, 18(1), 91-98.


Ren, J., Di, L., Song, G., Yu, J., Jia, J., Zhu, Y., . . . Che, L. (2013). Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clinical and Translational Oncology, 15(10), 780-788.


Schmidt-Wolf, I., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., . . . Takeya, M. (1999). Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British journal of cancer, 81(6), 1009-1016.


Shi, L., Zhou, Q., Wu, J., Ji, M., Li, G., Jiang, J., & Wu, C. (2012). Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunology, Immunotherapy, 61(12), 2251-2259.


Shi, M., Zhang, B., Tang, Z.-R., Lei, Z.-Y., Wang, H.-F., Feng, Y.-Y., . . . Wang, F.-S. (2004). Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World journal of gastroenterology, 10(8), 1146.


Shi, S. B., Ma, T. H., Li, C. H., & Tang, X. Y. (2012). Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori Journal, 98(3), 314-319.


Su, X., Zhang, L., Jin, L., Ye, J., Guan, Z., Chen, R., & Guo, T. (2010). Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer biotherapy & radiopharmaceuticals, 25(4), 465-470.


Wang, D., Zhang, B., Gao, H., Ding, G., Wu, Q., Zhang, J., . . . Chen, H. (2014). Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC cancer, 14(1), 251.


Wang, M., Shi, S.-b., Qi, J.-l., Tang, X.-y., & Tian, J. (2013). S-1 plus CIK as second-line treatment for advanced pancreatic cancer. Medical oncology, 30(4), 747.


Wang, Y., Bo, J., Dai, H.-r., Lu, X.-c., Lv, H.-y., Yang, B., . . . Han, W.-d. (2013). CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo. Experimental hematology, 41(3), 241-252. e243.


Wang, Z., Liu, X., Till, B., Sun, M., Li, X., & Gao, Q. (2018). Combination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcinoma and Non-Small Cell Lung Cancer. Frontiers in immunology, 9, 1513.


Wang, Z., Liu, Y., Shang, Y., Zhang, Y., Zhao, L., Li, W., . . . Nie, C. (2016). Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. Journal of hematology & oncology, 9(1), 6.


Wang, Z., Zhang, Y., Liu, Y., Wang, L., Zhao, L., Yang, T., . . . Gao, Q. (2014). Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. Journal of immunotherapy, 37(1), 43-50.


Wu, C., Jiang, J., Shi, L., & Xu, N. (2008). Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer research, 28(6B), 3997-4002.


Xie, Y., Huang, L., Chen, L., Lin, X., Chen, L., & Zheng, Q. (2017). Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. World journal of surgical oncology, 15(1), 209.


Xu, Y.-C., Xu, Q., Li, J.-J., Gu, X.-F., Lin, X.-L., Sun, L., . . . Lu, Z. (2016). Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial. Journal of cancer research and clinical oncology, 142(6), 1315-1323.


Yang, B., Lu, X. c., Yu, R. l., Chi, X. h., Liu, Y., Wang, Y., . . . Han, W. d. (2012). Repeated transfusions of autologous cytokine‐induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematological oncology, 30(3), 115-122.


Yang, L., Ren, B., Li, H., Yu, J., Cao, S., Hao, X., & Ren, X. (2013). Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunology, Immunotherapy, 62(1), 65-73.


Yoon, J. S., Song, B. G., Lee, J.-H., Lee, H. Y., Kim, S. W., Chang, Y., . . . Sinn, D. H. (2019). Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. BMC cancer, 19(1), 523.


Yu, J., Ren, X., Li, H., Cao, S., Han, Y., Enoki, T., . . . Hao, X. (2011). Synergistic effect of CH-296 and interferon gamma on cytokine-induced killer cells expansion for patients with advanced-stage malignant solid tumors. Cancer biotherapy & radiopharmaceuticals, 26(4), 485-494.


Yu, X., Zhao, H., Liu, L., Cao, S., Ren, B., Zhang, N., . . . Ren, X. (2014). A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma. Journal of clinical immunology, 34(2), 194-203.


Zhan, H.-l., Xin, G., PU, X.-y., Wei, L., LI, Z.-j., Zhou, X.-f., & Qiu, J.-g. (2012). A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chinese medical journal, 125(21), 3771-3777.


Zhang, C., Zhang, Z., Wang, L., Han, J., Li, F., Shen, C., . . . Yue, D. (2017). Pseudomonas aeruginosa-mannose sensitive hemagglutinin injection treated cytokine-induced killer cells combined with chemotherapy in the treatment of malignancies. International immunopharmacology, 51, 57-65.


Zhang, J., Li, H., Gao, D., Zhang, B., Zheng, M., Lun, M., . . . Hua, J. (2018). A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. Cancer biology & therapy, 19(6), 475-483.


Zhang, J., Zhu, L., Du, H., He, X., Yin, Y., Gu, Y., . . . Liu, P. (2015). Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study. Biomedicine & Pharmacotherapy, 70, 248-252.


Zhang, J., Zhu, L., Wei, J., Liu, L., Yin, Y., Gu, Y., & Shu, Y. (2012). The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. Journal of cancer research and clinical oncology, 138(6), 1057-1062.


Zhang, J., Zhu, L., Zhang, Q., He, X., Yin, Y., Gu, Y., . . . Liu, P. (2014). Effects of cytokine-induced killer cell treatment in colorectal cancer patients: A retrospective study. Biomedicine & Pharmacotherapy, 68(6), 715-720.


Zhang, L., Xu, Y., Shen, J., He, F., Zhang, D., Chen, Z., . . . Sun, J. (2016). Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Radiation Oncology, 11(1), 60.


Zhang, L., Xu, Z., Chen, X., Duan, Y., Chen, Z., & Sun, J. (2019). Clinical benefits of Livin peptide-loaded DCs/CIKs combined with chemotherapy in advanced non-small cell lung cancer. American journal of cancer research, 9(2), 406.


Zhang, Y., Wang, J., Wang, Y., Lu, X.-C., Fan, H., Liu, Y., . . . Chen, M.-X. (2013). Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clinical and Developmental Immunology, 2013.


Zhang, Z., Wang, L., Luo, Z., Zhao, X., Huang, J., Li, H., . . . Li, L. (2015). Efficacy and safety of cord blood–derived cytokine-induced killer cells in treatment of patients with malignancies. Cytotherapy, 17(8), 1130-1138.


Zhao, H., Fan, Y., Li, H., Yu, J., Liu, L., Cao, S., . . . Ren, X. (2013). Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biotherapy and Radiopharmaceuticals, 28(4), 303-309.


Zhao, H., Wang, Y., Yu, J., Wei, F., Cao, S., Zhang, X., . . . Ren, X. (2016). Autologous cytokine-induced killer cells improves overall survival of metastatic colorectal cancer patients: results from a phase II clinical trial. Clinical colorectal cancer, 15(3), 228-235.


Zhao, J.-J., Zhou, S., Chen, C.-L., Zhang, H.-X., Zhou, Z.-Q., Wu, Z.-R., . . . Tang, Y. (2018). Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis. Journal of Cancer, 9(22), 4204.


Zhao, P., Bu, X., Wei, X., Sun, W., Xie, X., Li, C., . . . Gao, D. (2015). Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer. International immunopharmacology, 25(2), 450-456.


Zhao, X., Zhang, Z., Li, H., Huang, J., Yang, S., Xie, T., . . . Wang, L. (2015). Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer letters, 362(2), 192-198.


Zhao, Y., Qiao, G., Wang, X., Song, Y., Zhou, X., Jiang, N., . . . Morse, M. (2019). Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients’ preference-based study (PPPS). Clinical and Translational Oncology, 21(6), 721-728.


Zheng, K., Tan, J.-M., Wu, W.-Z., Qiu, Y.-M., Zhang, H., Xu, T.-Z., . . . Zhang, J.-P. (2015). Adjuvant dendritic cells vaccine combined with cytokine-induced-killer cell therapy after renal cell carcinoma surgery. J BUON, 20(2), 505-513.


Zhong, R., Han, B., & Zhong, H. (2014). A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumor Biology, 35(2), 987-994.


Zhong, R., Teng, J., Han, B., & Zhong, H. (2011). Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunology, Immunotherapy, 60(10), 1497.


Zhou, P., Liang, P., Dong, B., Yu, X., Han, Z., & Xu, Y. (2011). Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer biology & therapy, 11(5), 450-456.


Zhou, X., Zhu, J., Sun, H., Shao, L., Xu, M., & Guo, H. (2013). Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting. Leukemia & lymphoma, 54(1), 209-211.


Zhou, Y., Chen, C.-l., Jiang, S.-w., Feng, Y., Yuan, L., Chen, P., . . . Xia, J.-C. (2019). Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. Oncoimmunology, 8(2), e1528411.


Zhou, Z., Qin, H., Weng, L., & Ni, Y. (2019). Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma. J. BUON, 24, 615-621.


Zhu, H., Yang, X., Li, J., Ren, Y., Zhang, T., Zhang, C., . . . Pang, Y. (2014). Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. BioMed Research International, 2014.


Zhu, Y., Zhang, H., Li, Y., Bai, J., Liu, L., Liu, Y., . . . Qu, X. (2013). Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. Cancer Immunology, Immunotherapy, 62(10), 1629-1635.